# | Title | Journal | Year | Citations |
---|
1 | IBMTR Severity INDEX FOR GRADING ACUTE GRAFT‐VERSUS‐HOST DISEASE: RETROSPECTIVE COMPARISON WITH GLUCKSBERG GRADE | British Journal of Haematology | 1997 | 605 |
2 | Fludarabine: a new agent with major activity against chronic lymphocytic leukemia | Blood | 1989 | 404 |
3 | Long-Term Follow-Up of Patients With Chronic Lymphocytic Leukemia (CLL) Receiving Fludarabine Regimens as Initial Therapy | Blood | 1998 | 394 |
4 | Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. | Journal of Clinical Oncology | 1998 | 331 |
5 | Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype [see comments] | Blood | 1992 | 313 |
6 | Fludarabine: a new agent with major activity against chronic lymphocytic leukemia | Blood | 1989 | 275 |
7 | Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes | Statistics in Medicine | 1995 | 258 |
8 | Richter's syndrome: a report on 39 patients. | Journal of Clinical Oncology | 1993 | 225 |
9 | Chemotherapy induces transient sex chromosomal and autosomal aneuploidy in human sperm | Nature Genetics | 1997 | 221 |
10 | Induction of apoptotic cell death in chronic lymphocytic leukemia by 2- chloro-2'-deoxyadenosine and 9-beta-D-arabinosyl-2-fluoroadenine | Blood | 1993 | 219 |
11 | Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma. | Journal of Clinical Oncology | 1992 | 203 |
12 | Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease. | Journal of Clinical Oncology | 1989 | 196 |
13 | 2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia | Blood | 1994 | 193 |
14 | L-Asparaginase and PEG Asparaginase— Past, Present, and Future | Leukemia and Lymphoma | 1993 | 174 |
15 | Detection of fusion transcripts generated by the inversion 16 chromosome in acute myelogenous leukemia | Blood | 1994 | 163 |
16 | Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis [see comments] | Blood | 1992 | 160 |
17 | Advances in the biology and treatment of B-cell chronic lymphocytic leukemia | Blood | 1995 | 159 |
18 | P-glycoprotein expression in plasma-cell myeloma is associated with resistance to VAD | Blood | 1989 | 152 |
19 | Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF | Blood | 1992 | 152 |
20 | Leukemia relapse after allogeneic bone marrow transplantation: a review | Blood | 1994 | 143 |
21 | A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels. | Journal of Clinical Oncology | 1989 | 142 |
22 | Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: a risk model. | Journal of Clinical Oncology | 1991 | 125 |
23 | A temperature-sensitive mutant of human p53. | EMBO Journal | 1994 | 118 |
24 | Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA) | Blood | 1992 | 116 |
25 | Detection of two alternative bcr/abl mRNA junctions and minimal residual disease in Philadelphia chromosome positive chronic myelogenous leukemia by polymerase chain reaction | Blood | 1989 | 112 |
26 | Philadelphia-chromosome-positive adult acute lymphocytic leukemia: Characteristics, treatment results, and prognosis in 41 patients | American Journal of Medicine | 1994 | 111 |
27 | Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia | Blood | 1993 | 108 |
28 | Fluorescent in situ hybridization and cytogenetic studies of trisomy 12 in chronic lymphocytic leukemia | Blood | 1993 | 106 |
29 | Allogeneic bone marrow transplantation for poor-prognosis lymphoma: Response, toxicity, and survival depend on disease histology | American Journal of Medicine | 1996 | 106 |
30 | Consensus review of the clinical utility of DNA flow cytometry in neoplastic hematopathology | Cytometry | 1993 | 104 |
31 | Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy | Blood | 1998 | 102 |
32 | Plasma cell myeloma--new biological insights and advances in therapy | Blood | 1989 | 100 |
33 | Risk classification as the basis for clinical staging of diffuse large- cell lymphoma derived from 10-year survival data | Blood | 1989 | 98 |
34 | Combined modality therapy for cutaneous T-cell lymphoma | Journal of the American Academy of Dermatology | 1996 | 95 |
35 | Association between increased body mass index and a diagnosis of acute promyelocytic leukemia in patients with acute myeloid leukemia | Leukemia | 1997 | 92 |
36 | Rearrangement and expression of p53 in the chronic phase and blast crisis of chronic myelogenous leukemia | Blood | 1990 | 88 |
37 | Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A | Oncogene | 1997 | 86 |
38 | Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma. | Journal of Clinical Oncology | 1994 | 85 |
39 | Molecular characterization of 16p deletions associated with inversion 16 defines the critical fusion for leukemogenesis | Blood | 1995 | 84 |
40 | Fludarabine: a new agent with major activity against chronic lymphocytic leukemia | Blood | 1989 | 82 |
41 | Lack of Effect of 2-Chlorodeoxyadenosine Therapy in Patients with Chronic Lymphocytic Leukemia Refractory to Fludarabine Therapy | New England Journal of Medicine | 1994 | 81 |
42 | Lymphomatoid Papulosis: A T-Cell Dyscrasia with a Propensity To Transform into Malignant Lymphoma | Annals of Internal Medicine | 1995 | 81 |
43 | Epidemiology of Influenza A virus infection in patients with acute or chronic leukemia | Supportive Care in Cancer | 1995 | 80 |
44 | Fatal pulmonary failure complicating high-dose cytosine arabinoside therapy in acute leukemia | Cancer | 1990 | 78 |
45 | Collection and transfusion of granulocyte concentrates from donors primed with granulocyte stimulating factor and response of myelosuppressed patients with established infection | Journal of Clinical Apheresis | 1995 | 75 |
46 | CBFβ-SMMHC, expressed in M4Eo AML, reduced CBF DNA-binding and inhibited the G1 to S cell cycle transition at the restriction point in myeloid and lymphoid cells | Oncogene | 1997 | 75 |
47 | Phenotypic and molecular heterogeneity in Philadelphia chromosome- positive acute leukemia | Blood | 1988 | 74 |
48 | Effects of low doses of recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with myelodysplastic syndromes | British Journal of Haematology | 1991 | 74 |
49 | Effect of prior interferon alfa therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia. | Journal of Clinical Oncology | 1993 | 74 |
50 | Treatment of Waldenstrom's macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: Identification of prognostic factors | Annals of Oncology | 1995 | 73 |